Shanghai RAAS expands SR604 injection clinical trials

Shanghai RAAS Blood Products announced that China's National Medical Products Administration accepted its application to expand clinical trial indications for SR604 Injection to include "preventive treatment of bleeding episodes in patients with von Willebrand disease."

SR604 Injection is already in clinical trials for hemophilia A/B and congenital factor VII deficiency. The company plans Phase II dose-finding trials for von Willebrand disease, exploring various dosages from 0.2mg/kg to 0.4mg/kg administered every four to eight weeks.

No other products targeting the same mechanism or antibody drugs for von Willebrand disease prevention are currently on the global market.